At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
In Brief
A Phase 2 clinical trial evaluating Anti-Endoglin Chimeric Monoclonal Antibody TRC105, Bevacizumab, and 2 other interventions for Clear Cell Renal Cell Carcinoma and 4 related conditions. Completed, enrolled 59 participants across 30 sites in 3 countries.
Detailed Summary
This randomized phase II trial studies how well bevacizumab with or without anti-endoglin monoclonal antibody TRC105 (TRC105) works in treating patients with kidney cancer that has spread to other parts of the body (metastatic). Monoclonal antibodies, such as bevacizumab and anti-endoglin monoclonal antibody TRC105, may block tumor growth in different ways by targeting certain cells.
Study Details
Timeline
Interventions
Given IV
Given IV
Correlative studies
Correlative studies